N-(哌啶-2-甲基)乙胺 | 120990-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-(哌啶-2-甲基)乙胺
• 中文别名: N-乙基-2-哌啶甲胺
• 英文名称: ethyl-piperidin-2-ylmethyl-amine
• 英文别名: 2-Ethylaminomethyl-piperidin；N-(Piperidin-2-ylmethyl)ethanamine
• CAS: 120990-88-7
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: HXNVNBQRMGFOTB-UHFFFAOYSA-N

物化性质

• 沸点：
  199℃
• 密度：
  0.860
• 闪点：
  74℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N-(哌啶-2-甲基)乙胺 、 5,11-二氢-11-氯乙酰基-6H-吡啶并[2.3-b][1,4]苯并二氮卓-6-酮 在 sodium carbonate 作用下， 以 乙腈 为溶剂， 反应 5.0h， 生成 11-[2-(2-Ethylaminomethyl-piperidin-1-yl)-acetyl]-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one
  参考文献：
  名称：

  Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics

  摘要：

  On the basis of the cardioselective muscarinic receptor antagonist AF-DX 116 (2), a series of 11-substituted pyridobenzodiazepinones (9-35) was prepared and screened for their binding affinity to muscarinic receptors located in cardiac (M2) and glandular (M3) tissue. The ratio of IC50 values of the test compounds in the two different tissues was taken as a measure of cardiac (M2) receptor selectivity. Qualitative structure-selectivity relationships point to the fact that it is the spatial orientation of the protonated side-chain nitrogen atom in relation to the tricycle that is the main determinant for receptor subtype recognition and hence is important for the achievement of cardiac (M2) selectivity.

  DOI：

  10.1021/jm00128a008

文献信息

• NOVEL THIENOPYRROLE COMPOUNDS
  申请人：Wishart Neil

  公开号：US20110152243A1

  公开（公告）日：2011-06-23

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了公式（I）的化合物，包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可用于治疗免疫和肿瘤疾病。
• Process for Production of Optically Active Quinuclidinols
  申请人：Noyori Ryoji

  公开号：US20090216019A1

  公开（公告）日：2009-08-27

  A novel ruthenium complex which is a highly efficient catalyst useful for the production of optically active 3-quinuclidinols, and a process for production of optically active 3-quinuclidinols using the ruthenium complex as a catalyst, where the optically active 3-quinuclidinols are useful as an optically active, physiologically active compound utilized in medicines and agrichemicals or as a synthetic intermediate such as a liquid crystal material.

  一种新颖的钌配合物，是一种高效催化剂，可用于生产光学活性的3-喹诺啉醇，并且提供一种以该钌配合物为催化剂生产光学活性3-喹诺啉醇的方法，其中光学活性的3-喹诺啉醇可用作光学活性、生理活性的化合物，用于药物和农药，或者作为合成中间体，如液晶材料。
• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Penning Thomas D.

  公开号：US20110257152A1

  公开（公告）日：2011-10-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及式（I）的化合物或药物可接受的盐，其中R1a，R1b，R1c，X和Y在说明中有定义。本发明还涉及含有所述化合物的组合物，其对于抑制Cdc7等激酶以及治疗癌症等疾病的方法是有用的。
• 10a-Azalide Compound
  申请人：Sugimoto Tomohiro

  公开号：US20090281292A1

  公开（公告）日：2009-11-12

  [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae , erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

  【目标】提供一种具有新结构的化合物，对流感嗜血杆菌和红霉素耐药菌（例如耐药肺炎球菌和链球菌）以及传统的红霉素敏感菌具有有效作用。 【解决方案】本发明提供了一种新型10a-氮杂环十六元化合物，其化学式为（I），其药学上可接受的盐或其溶剂化物，或其制备的中间体。该化合物对流感嗜血杆菌、红霉素耐药性肺炎球菌等具有卓越的抗菌活性，因此可以作为治疗传染病的药物。
• Aminosäurederivate
  申请人：MERCK PATENT GmbH

  公开号：EP0371390A2

  公开（公告）日：1990-06-06

  Neue Aminosäurederivate der Formel I R¹-Z-NR²-CHR³-CR⁴-(CHR⁵)a-CO-E-Q-Y      I worin R¹ bis R⁵, a, Z, E, Q und Y die in Patentanspruch 1 angegebenen Bedeutungen haben, sowie ihre Salze hemmen die Aktivität des menschlichen Plasmarenins.

  式 I 的新型氨基酸衍生物 R¹-Z-NR²-CHR³-CR⁴-(CHR⁵)a-CO-E-Q-Y I 其中 R¹ 至 R⁵、a、Z、E、Q 和 Y 具有权利要求 1 中给出的含义、 及其盐类可抑制人血浆肾素的活性。